Literature DB >> 21909592

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe.

Kurt Huber, K Juhani Airaksinen, Thomas Cuisset, Francisco Marín, Andrea Rubboli, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21909592     DOI： 10.1160/TH11-08-0602

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  10 in total

1.  Use of novel oral anticoagulants in patients with heart failure.

Authors:  Eduard Shantsila; Gregory Y H Lip
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

2.  Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.

Authors:  Connie N Hess; Samuel Broderick; Jonathan P Piccini; Karen P Alexander; L Kristin Newby; Linda K Shaw; Kenneth W Mahaffey; John H Alexander; Eric D Peterson; Christopher B Granger; Renato D Lopes
Journal:  Am Heart J       Date:  2012-10       Impact factor: 4.749

3.  Oral antiplatelet therapy in acute coronary syndromes: update 2012.

Authors:  Thomas Höchtl; Peter R Sinnaeve; Tom Adriaenssens; Kurt Huber
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-04

4.  Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation.

Authors:  James A Nelson; John P Vavalle; Christopher H May; Aijing Zhang; L Kristin Newby; Linda K Shaw; Sana M Al-Khatib; John H Alexander; Christopher B Granger; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

Review 5.  Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.

Authors:  Jonathan Douxfils; Helen Mani; Valentine Minet; Bérangère Devalet; Bernard Chatelain; Jean-Michel Dogné; François Mullier
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

6.  Prevalence, Epidemiological Characteristics, and Pharmacotherapy of Coronary Artery Disease among Patients with Atrial Fibrillation: Data from Jo-Fib Study.

Authors:  Hanna K Al-Makhamreh; Mohammed Q Al-Sabbagh; Ala' E Shaban; Abdelrahman F Obiedat; Ayman J Hammoudeh
Journal:  Medicina (Kaunas)       Date:  2021-06-11       Impact factor: 2.430

Review 7.  Left Atrial Appendage: Physiology, Pathology, and Role as a Therapeutic Target.

Authors:  Damiano Regazzoli; Francesco Ancona; Nicola Trevisi; Fabrizio Guarracini; Andrea Radinovic; Michele Oppizzi; Eustachio Agricola; Alessandra Marzi; Nicoleta Carmen Sora; Paolo Della Bella; Patrizio Mazzone
Journal:  Biomed Res Int       Date:  2015-07-07       Impact factor: 3.411

Review 8.  Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.

Authors:  K Huber; S J Connolly; A Kher; F Christory; G-A Dan; R Hatala; R G Kiss; B Meier; B Merkely; B Pieske; T Potpara; J Stępińska; N Vene Klun; D Vinereanu; P Widimský
Journal:  Int J Clin Pract       Date:  2013-04-05       Impact factor: 2.503

9.  Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.

Authors:  Laurent Fauchier; Nicola Greenlaw; Roberto Ferrari; Ian Ford; Kim M Fox; Jean-Claude Tardif; Michal Tendera; Ph Gabriel Steg
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

10.  Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: A PRISMA-compliant article.

Authors:  Junquan Zeng; Peng Yu; Wenjuan Cui; Xiaoping Wang; Jianyong Ma; Changai Zeng
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.